Zymeworks Inc. (ZYME)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-10

Key Insights

Insider Scott Platshon, EVP and Chief Business Officer, acquired 70,000 stock options, 47,000 restricted stock units, and 76,000 performance stock units, indicating potential confidence in the company's future performance.
The significant equity awards granted to Platshon suggest the company is incentivizing its leadership to drive long-term value creation for shareholders.
The stock option grant has a 10-year expiration, aligned with Platshon's long-term commitment to the company.

Insider Trading Filed: 2026-04-10

Key Insights

Adam Schayowitz, the Executive Vice President and Head of Research & Development, has acquired 70,000 stock options, 47,000 restricted stock units, and 76,000 performance stock units, indicating the company's confidence in his leadership and the long-term growth potential.
The vesting schedules for the stock options, restricted stock units, and performance stock units suggest that the company is incentivizing Schayowitz to remain with the company and drive long-term performance.
The performance stock units are tied to the company's total shareholder return (TSR) relative to the Nasdaq Biotech Index, aligning Schayowitz's interests with those of Zymeworks Inc. shareholders.

Insider Trading Filed: 2026-04-07

Key Insights

Kristin Stafford, the EVP and Chief Financial Officer of Zymeworks Inc., acquired 178,000 stock options and 169,000 restricted stock units on April 6, 2026, indicating potential confidence in the company's future performance.
The stock options have a strike price of $25.84 and vest over 4 years, while the restricted stock units vest in a combination of 4 and 3 annual installments, suggesting a long-term incentive structure.
The significant size of the equity awards, representing a substantial increase in Stafford's beneficial ownership, may signal her belief in Zymeworks' growth potential.

Insider Trading Filed: 2026-01-13

Key Insights

Brian N. Cherry, a director of Zymeworks Inc., has acquired 23,000 stock options and 15,400 restricted stock units, indicating their confidence in the company's future performance.
The stock options have a strike price of $23.16 and vest over 36 months, aligning the director's interests with long-term shareholder value creation.
The restricted stock units vest over three years, further incentivizing the director to contribute to the company's success in the coming years.

Insider Trading Filed: 2026-01-13

Key Insights

The EVP and Chief Operating Officer, Mark Hollywood, exercised 17,666 restricted stock units (RSUs) and sold 6,120 shares to cover tax withholding obligations.
In addition to the RSUs, Hollywood was granted 70,000 stock options, 47,000 RSUs, and 66,000 performance stock units (PSUs) with a three-year performance period.
The insider trading activity represents a mix of vesting, selling to cover taxes, and new equity grants, which suggests ongoing alignment between management and shareholders.

Current Report Filed: 2026-01-12

Key Insights

Zymeworks Inc. has reported a strong cash position of approximately $270.6 million as of December 31, 2025, indicating financial stability and the potential to fund planned operations beyond 2028.
The company announced a $125 million share repurchase plan and expects to receive $440 million in regulatory milestone payments, further strengthening its financial outlook.
The board has appointed Brian Cherry as a new director, bringing additional expertise to the company's leadership team.
The termination of Chief Financial Officer Leone Patterson is not due to any disagreement, and Kenneth Galbraith has been appointed as interim CFO.

Insider Trading Filed: 2026-01-12

Key Insights

The Chair and CEO, Kenneth Galbraith, exercised 64,000 restricted stock units (RSUs) and sold 30,424 shares to cover tax withholding obligations, indicating ongoing confidence in the company's future.
Galbraith was also granted an additional 216,000 stock options and 144,000 RSUs, aligning his interests with shareholders through long-term equity incentives.
The company also granted Galbraith 222,000 performance stock units (PSUs), which are contingent on achieving cumulative total shareholder return goals over a three-year period, further incentivizing strong long-term performance.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.